MARKETSACTIVE
1 hour ago
Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
SIGNALSMONITORMARKETS
What's happening
SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 11 Nov 2026, 01:40 UTC. The headline in use is “Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by Seeking Alpha
Reported by 1 outlet
- Seeking Alpha